News Snapshot:
Antengene, a China- and US-based cancer drug developer backed by Boyu Capital, has raised about HK$2.8 billion ($361 million) in an initial public offering (IPO) on the Main Board of the Hong Kong stock exchange on Friday. Create an account to continue reading our free content. Register Already have an account? Sign in here
